MedTrace Logo

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

NCT06862284 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-11

No results posted yet for this study

Summary

This study is designed to explore the efficacy and safety of upadacitinib and clarify the influence on immune function in the treatment of primary Sjögren's Syndrome.

Conditions

  • Primary Sjögren's Syndrome (pSS)

Interventions

DRUG

Upadacitinib (ABT-494)

Upadacitinib 15mg Qd for 52 weeks

DRUG

Hydroxychloroquine (HCQ)

Hydroxychloroquine 200mg Bid for 52 weeks

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Jing He · Peking University Institute of Rheuamotology and Immunology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2026-12-30
Completion
2027-08-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06862284 on ClinicalTrials.gov